- glycogen storage disease type III Type A
- glycogen storage disease type III Type B
- Others
Glycogen storage disease type III Market size was valued at USD XX million in 2023 and is expected to grow at an XX% CAGR from 2024-2030. Glycogen Storage Disease Type III, also known as Cori disease or Forbes disease, is a rare inherited metabolic disorder characterized by the body's inability to properly break down glycogen. This condition results from mutations in the AGL gene, which provides instructions for producing the glycogen debranching enzyme. Recent statistics indicate that glycogen storage disease type III affects approximately 1 in 100,000 individuals worldwide, with higher prevalence in certain populations such as North African Jews, where incidence rates can reach 1 in 5,400. The market has seen a surge in research activities, with the number of clinical trials for glycogen storage disease type III treatments increasing in past five years. Key drivers of the glycogen storage disease type III market include rising diagnosis rates, improved genetic testing capabilities, and growing patient advocacy efforts. The development of enzyme replacement therapies and gene therapies presents significant opportunities for market growth. However, the market faces challenges such as the high cost of treatment and limited awareness among healthcare professionals in some regions.
Current trends in the glycogen storage disease type III market include a focus on personalized medicine approaches, increased collaboration between pharmaceutical companies and research institutions, and the exploration of combination therapies. The market has also witnessed a growing emphasis on improving quality of life for patients through better management strategies and supportive care. In recent years, there has been a notable increase in funding for rare disease research, with glycogen storage disease type III benefiting from initiatives such as the NIH's Rare Diseases Clinical Research Network. This has led to a 25% increase in publications related to glycogen storage disease type III over the past three years, indicating growing scientific interest and potential for new therapeutic developments. The COVID-19 pandemic has had a mixed impact on the glycogen storage disease type III market. While it initially caused disruptions in clinical trials and patient care, it has also accelerated the adoption of telemedicine and remote monitoring technologies, potentially improving access to specialized care for glycogen storage disease type III patients in remote areas.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The Glycogen Storage Disease Type III market is propelled by dynamics such as increasing awareness and diagnosis rates, and advancements in research and development. Growing awareness, driven by patient advocacy groups like the Association for Glycogen Storage Disease, has led to a 40% increase in member engagement over five years. Improved genetic testing, particularly next-generation sequencing, has boosted diagnosis accuracy to over 95% for AGL gene mutations. Simultaneously, R&D advancements have significantly impacted the glycogen storage disease type III market. Clinical trials for glycogen storage disease type III treatments have increased by 30% in the past three years, as evidenced by clinicaltrials.gov registrations. Pharmaceutical companies are investing in novel approaches such as enzyme replacement and gene therapies, with promising preclinical results for mRNA-based treatments. These dynamics are creating a robust pipeline of potential therapies, addressing the unmet medical needs of patients, and driving glycogen storage disease type III market growth despite the condition's rarity.
Pfizer Inc., Novo Nordisk A/S, Amicus Therapeutics, Inc., and Regeneron Pharmaceuticals, Inc. are some of the major players operating in the glycogen storage disease type III market.
Asia Pacific is estimated to grow at the highest CAGR over the forecast period.
North America accounts for the largest market share and is expected to be the primary market driver in the glycogen storage disease type III market.
Key challenges include the rarity of the disease, limited understanding of its long-term progression, and difficulties in conducting large-scale clinical trials due to the small patient population.
1.Executive Summary |
2.Global Glycogen Storage Disease Type III Market Introduction |
2.1.Global Glycogen Storage Disease Type III Market - Taxonomy |
2.2.Global Glycogen Storage Disease Type III Market - Definitions |
2.2.1.Disease type |
2.2.2.Treatment |
2.2.3.End User |
2.2.4.Region |
3.Global Glycogen Storage Disease Type III Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Glycogen Storage Disease Type III Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Glycogen Storage Disease Type III Market By Disease type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. glycogen storage disease type III Type A |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. glycogen storage disease type III Type B |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Others |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6.Global Glycogen Storage Disease Type III Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Dietary Management |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Supportive Care |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Enzyme Replacement Therapy |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Gene Therapy |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Glycogen Storage Disease Type III Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Specialty Clinics |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Research Institutes |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Glycogen Storage Disease Type III Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Glycogen Storage Disease Type III Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.glycogen storage disease type III Type A |
9.1.2.glycogen storage disease type III Type B |
9.1.3.Others |
9.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Dietary Management |
9.2.2.Supportive Care |
9.2.3.Enzyme Replacement Therapy |
9.2.4.Gene Therapy |
9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Specialty Clinics |
9.3.3.Research Institutes |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Glycogen Storage Disease Type III Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Disease type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.glycogen storage disease type III Type A |
10.1.2.glycogen storage disease type III Type B |
10.1.3.Others |
10.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Dietary Management |
10.2.2.Supportive Care |
10.2.3.Enzyme Replacement Therapy |
10.2.4.Gene Therapy |
10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Specialty Clinics |
10.3.3.Research Institutes |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Glycogen Storage Disease Type III Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Disease type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.glycogen storage disease type III Type A |
11.1.2.glycogen storage disease type III Type B |
11.1.3.Others |
11.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Dietary Management |
11.2.2.Supportive Care |
11.2.3.Enzyme Replacement Therapy |
11.2.4.Gene Therapy |
11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Specialty Clinics |
11.3.3.Research Institutes |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Glycogen Storage Disease Type III Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Disease type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.glycogen storage disease type III Type A |
12.1.2.glycogen storage disease type III Type B |
12.1.3.Others |
12.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Dietary Management |
12.2.2.Supportive Care |
12.2.3.Enzyme Replacement Therapy |
12.2.4.Gene Therapy |
12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Specialty Clinics |
12.3.3.Research Institutes |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Glycogen Storage Disease Type III Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Disease type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.glycogen storage disease type III Type A |
13.1.2.glycogen storage disease type III Type B |
13.1.3.Others |
13.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Dietary Management |
13.2.2.Supportive Care |
13.2.3.Enzyme Replacement Therapy |
13.2.4.Gene Therapy |
13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Specialty Clinics |
13.3.3.Research Institutes |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Ultragenyx Pharmaceutical Inc. |
14.2.2.Alexion Pharmaceuticals Inc. |
14.2.3.AstraZeneca |
14.2.4.Sanofi S.A. |
14.2.5.Takeda Pharmaceutical Company Limited |
14.2.6.BioMarin Pharmaceutical Inc. |
14.2.7.Spark Therapeutics |
14.2.8.Roche |
14.2.9.Pfizer Inc. |
14.2.10.Novo Nordisk A/S |
14.2.11.Amicus Therapeutics, Inc. |
14.2.12.Regeneron Pharmaceuticals, Inc. |
14.2.13.Vertex Pharmaceuticals Incorporated |
14.2.14.Genzyme Corporation |
14.2.15.Sanofi |
14.2.16.Shire Pharmaceuticals |
14.2.17.Takeda |
14.2.18.Abeona Therapeutics Inc. |
15. Research Methodology |
16. Appendix and Abbreviations |